Introduction Up to 32% of patients with esophageal cancer show a pathological complete
response (ypCR) after neoadjuvant therapy. To prevent overtreatment, the indication to …

This is one of a series of statements discussing the use of GI endoscopy in common clinical
situations. The Standards of Practice Committee of the American Society for Gastrointestinal …

Background After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma …

Background The aim of this study was to report on the 5-year survival outcomes of patients
with resectable esophageal carcinoma who were treated by definitive chemoradiotherapy …

Objective: The aim of this study was to perform a meta-analysis on the accuracy of
endoscopic biopsies, EUS, and 18F-FDG PET (-CT) for detecting residual disease after …

Leakage from the esophagus and gastroesophageal junction can be lethal due to
uncontrolled contamination of the mediastinum. The most predominant risk factors for the …

Background and Aims Accurate determination of residual cancer status after neoadjuvant
chemoradiotherapy (nCRT) for esophageal cancer could assist in selecting the optimal …

Background: Results from the recent CROSS trial showed that neoadjuvant
chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in …

Objectives: To gain insight into the exact location of residual esophageal cancer in the
esophageal wall and regional lymph nodes after neoadjuvant chemoradiotherapy (nCRT) …

Background After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high
pathologically complete response (pCR) rates are being achieved especially in patients with …